Jim Cramer on AstraZeneca: "We Want Every Drug Stock"

AstraZeneca PLC (NASDAQ:AZN) is one of the stocks in focus on Jim Cramer’s game plan. Cramer mentioned the company during the episode and said:

On Tuesday, we’re back in heavy earnings rotation. We’ve got DuPont, Coca-Cola, CVS Health, AstraZeneca, Datadog, and S&P Global report… Oh, also, AstraZeneca, we want every drug stock. They’re all working.

AstraZeneca PLC (NASDAQ:AZN) manufactures prescription medicines for oncology, cardiovascular, respiratory, and rare diseases. During the January 30 episode, a caller mentioned that they were contemplating selling their position in the company’s stock for profit and buying ABBV. Cramer replied:

I like AstraZeneca very much. And that cancer franchise turned out to be a lot stronger than I thought. I think you should hold onto that. AbbVie reports this week. I expect a very good quarter. I like the dividend, but I think AstraZeneca has got a better portfolio at this very moment.

While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.